Follow us on:

Cizzle Biotechnology programme with US firm Bio-Techne takes major step forward (VIDEO)

Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to the completion of its Evaluation Programme with Bio-Techne for Cizzle’s CIZ1B cancer biomarker.

Allan reminds us of what the CIZ1B biomarker is, how this helps with the detection of early-stage lung cancer, why is Bio-Techne a good fit for Cizzle, how Cizzle intends to build on this relationship with Bio-Techne and bring its diagnostic solution to market and how Allan sees the outlook for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO)

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

More News

Cizzle Biotechnology Completes Evaluation Programme with Bio-Techne September 19, 2023
Cizzle Biotechnology Holdings Update and Extension on Put Option with Conduit September 8, 2023
Cizzle Biotechnology Holdings Put Option Update with Conduit August 15, 2023
Cizzle Biotechnology Expands Research Agreement with the University of York August 10, 2023
Cizzle Biotechnology raise £350,000 to progress proprietary CIZ1B June 12, 2023
Cizzle Biotechnology creating new solutions for early cancer diagnostics and therapeutic tools April 27, 2023
Cizzle Biotechnology announces voluntary director salary waivers and share options March 7, 2023
Cizzle Biotechnology put option for sale of economic interest and royalty sharing agreement in AZD1656 December 19, 2022
Cizzle Biotechnology significant progress made during the first half of 2022 September 28, 2022
Cizzle Biotechnology update on development of proprietary antibodies July 5, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.